Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord mesenchymal stem cells (UC-MSCs) are an allogeneic cell therapy being developed by RSUP Persahabatan in collaboration with PT Prostem for the treatment of Group E Chronic Obstructive Pulmonary Disease (COPD). Administered intravenously as an adjuvant to standard triple inhalation therapy (LABA, LAMA, and ICS), these stem cells are intended to modulate the inflammatory response and potentially facilitate lung tissue repair. The therapy is currently being evaluated in a Phase 2 clinical trial to assess its safety and efficacy in improving pulmonary function, quality of life, and exercise capacity (measured by the 6-minute walk test) in patients with advanced COPD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (RSUP Persahabatan).